Skip to main content
Search
Main content
Science (New York, N.Y.)
Published

Pharmacological modulation of septins restores calcium homeostasis and is neuroprotective in models of Alzheimer's disease

Authors

Katrien Princen, Tom Van Dooren, Marit van Gorsel, Nikolaos Louros, Xiaojuan Yang, Michael Dumbacher, Ilse Bastiaens, Kristel Coupet, Shana Dupont, Eva Cuveliers, Annick Lauwers, Mohamed Laghmouchi, Thomas Vanwelden, Sofie Carmans, Nele Van Damme, Hein Duhamel, Seppe Vansteenkiste, Jovan Prerad, Karolien Pipeleers, Olivier Rodiers, Liese De Ridder, Sofie Claes, Yoni Busschots, Lentel Pringels, Vanessa Verhelst, Eveline Debroux, Marinka Brouwer, Sam Lievens, Jan Tavernier, Melissa Farinelli, Sandrine Hughes-Asceri, Marieke Voets, Joris Winderickx, Stefaan Wera, Joris de Wit, Joost Schymkowitz, Frederic Rousseau, Henrik Zetterberg, Jeffrey L Cummings, Wim Annaert, Tom Cornelissen, Hans De Winter, Koen De Witte, Marc Fivaz, Gerard Griffioen

Abstract

Science. 2024 May 31;384(6699):eadd6260. doi: 10.1126/science.add6260. Epub 2024 May 31.

ABSTRACT

Abnormal calcium signaling is a central pathological component of Alzheimer's disease (AD). Here, we describe the identification of a class of compounds called ReS19-T, which are able to restore calcium homeostasis in cell-based models of tau pathology. Aberrant tau accumulation leads to uncontrolled activation of store-operated calcium channels (SOCCs) by remodeling septin filaments at the cell cortex. Binding of ReS19-T to septins restores filament assembly in the disease state and restrains calcium entry through SOCCs. In amyloid-β and tau-driven mouse models of disease, ReS19-T agents restored synaptic plasticity, normalized brain network activity, and attenuated the development of both amyloid-β and tau pathology. Our findings identify the septin cytoskeleton as a potential therapeutic target for the development of disease-modifying AD treatments.

PMID:38815015 | DOI:10.1126/science.add6260

UK DRI Authors

Profile picture of Henrik Zetterberg

Prof Henrik Zetterberg

Group Leader

Pioneering the development of fluid biomarkers for dementia

Prof Henrik Zetterberg